262 related articles for article (PubMed ID: 29027246)
1. Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
Ghith A; Ismail NSM; Youssef K; Abouzid KAM
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 29027246
[TBL] [Abstract][Full Text] [Related]
2. Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Ali EMH; Abdel-Maksoud MS; Oh CH
Bioorg Med Chem; 2019 Apr; 27(7):1159-1194. PubMed ID: 30826188
[TBL] [Abstract][Full Text] [Related]
3. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
[TBL] [Abstract][Full Text] [Related]
5. Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties.
Bugge S; Buene AF; Jurisch-Yaksi N; Moen IU; Skjønsfjell EM; Sundby E; Hoff BH
Eur J Med Chem; 2016 Jan; 107():255-74. PubMed ID: 26599532
[TBL] [Abstract][Full Text] [Related]
6. Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
Pathania S; Rawal RK
Eur J Med Chem; 2018 Sep; 157():503-526. PubMed ID: 30114661
[TBL] [Abstract][Full Text] [Related]
7. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
8. Eco-friendly Synthesis of Pyrido[2,3-d]pyrimidine Analogs and Their Anticancer and Tyrosine Kinase Inhibition Activities.
El-Naggar AM; Khalil AK; Zeidan HM; El-Sayed WM
Anticancer Agents Med Chem; 2017; 17(12):1644-1651. PubMed ID: 28403776
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and Biological Evaluation of Some 5-Arylthieno[2,3-d]pyrimidines as Potential Anti-cancer Agents.
El-Ansary AK; Kamal AM; Al-Ghorafi MA
Chem Pharm Bull (Tokyo); 2016; 64(8):1172-80. PubMed ID: 27477657
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Drug Res (Stuttg); 2018 Sep; 68(9):485-498. PubMed ID: 29433143
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
[TBL] [Abstract][Full Text] [Related]
14. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
15. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
Wu K; Ai J; Liu Q; Chen T; Zhao A; Peng X; Wang Y; Ji Y; Yao Q; Xu Y; Geng M; Zhang A
Bioorg Med Chem Lett; 2012 Oct; 22(20):6368-72. PubMed ID: 22985853
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic drug potential of oxazolo[5,4-d]pyrimidines and oxazolo[4,5-d]pyrimidines.
Zhirnov VV; Velihina YS; Mitiukhin OP; Brovarets VS
Chem Biol Drug Des; 2021 Oct; 98(4):561-581. PubMed ID: 34148293
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors.
Lin S; Wang C; Ji M; Wu D; Lv Y; Sheng L; Han F; Dong Y; Zhang K; Yang Y; Li Y; Chen X; Xu H
Bioorg Med Chem; 2018 Feb; 26(3):637-646. PubMed ID: 29305298
[TBL] [Abstract][Full Text] [Related]
20. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
